- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Fingerpaint Group Acquires The MYND Group, Bolstering Market Access Capabilities
Fingerpaint Group, a collective of healthcare companies providing commercialization solutions, is expanding its market access capabilities with the acquisition of The MYND Group, a strategic market access marketing company specializing in pharmaceuticals and biologics.
The MYND Group will enhance Fingerpaint's market access strategy, research, and launch experience. Jonathan Magid will continue leading The MYND Group as Managing Director, reporting to Brannon Cashion, President of Specialty Services at Fingerpaint Group.
Fingerpaint Group has seen significant growth since partnering with private equity firm Knox Lane in 2020.
Reference: Fingerpaint Group Acquires The MYND Group, Bolstering Its Robust Market Access Capabilities. April 4, 2023 / Fingerpaint
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
